COVID-19 Clinical Trials and Expanded Access

This is a prospective observational cohort study that will define the prevalence andincidence of CA-SARS-Cov2 infection using serological and PCR tests in a group ofsubjects during deconfinement. The team wishes to include approximately 1000 subjects inthis study.The health crisis through containment has also created unprecedented environmentalconditions with the very clear decrease in economic activities and a consequent decreasein exposure to the main air pollutants. The aim is therefore to carry out a case-controlstudy in which each subject will be his or her own control in unexposed condition (toPM2.5, PM10, NO...) then exposed (after the recovery of economic activity and the usuallevels of air pollutants) and to measure the impact of these pollutants on the immunesystem and epigenetic markers taking into account seasonality.The occurrence of infectious, cardiovascular, allergic and autoimmune events will then bemeasured according to the immunological profiles measured at inclusion.

Low doses of radiation in the form of chest X-rays have been used to treat people withpneumonia. This treatment was found to be effective by reducing inflammation and withminimal side effects. However, it was an expensive treatment and was eventually replacedwith less costly treatments such as antibiotics. Radiation has also been shown in someanimal experiments to reduce some types of inflammation.Some patients diagnosed with COVID-19 pneumonia will experience worsening disease, whichcan become very serious, requiring the use of a ventilator. This is caused byinflammation in the lung from the virus and the immune system. For this study, the x-raygiven is called radiation therapy. Radiation therapy uses high-energy X-ray beams from alarge machine to target the lungs and reduce inflammation. Usually, it is given at muchhigher doses to treat cancers.The purpose of this study is to find out if adding a single treatment of low-dose x-raysto the lungs might reduce the amount of inflammation in the lungs from a COVID-19infection, which could help a patient to breathe without use of a ventilator.

Richmond Research Institute (RRI) is applying existing and new COVID-19 PCR and antibodytests to help develop methodologies which provide fast and accurate results. Infectionwith coronavirus (SARS-CoV-2) is currently a worldwide pandemic and reliable testing forCOVID-19 is crucial to understand who is infected and therefore a risk to others byspreading the infection. RRI are currently carrying out the following tests:A. Using a membrane-based immunoassay to detect IgG and IgM antibodies to SARS-CoV-2 inwhole blood, serum or plasma specimens helps to assess whether an individual haspreviously had the virus and is potentially immuneB. Polymerase Chain Reaction (PCR) testing using an established method to check foractive SARS-CoV-2 infections.C. Quantification of anti-SARS-CoV-2 IgG and IgM antibodies in whole blood samples.The above tests are being used by RRI to follow infections (PCR) and immunity (IgG) intheir workforce, as well as their families (including children) and visitors to theirsite.Collecting this data allows the gathering of epidemiological data on SARS-CoV-2 includingincidence, prevalence, information on asymptomatic carriers and efficacy of vaccination.Furthermore, identifying individuals that are infected with SARS-CoV-2 has greatpotential to improve health outcomes by allowing infected individuals to seek the correctmedical treatment as well as self-isolate and reduce transmission.

This is study is comprised of three approaches. First, the investigators will conduct aretrospective cohort study to determine factors associated with COVID-19 severity andcomplications and understand COVID-19 outcomes, including all-cause mortality,post-discharge events, and impacts of rehabilitation services (third aim). The second aimis a mixed-method study and follows COVID-19 patients with repeated surveys to determinepatient-reported functional outcomes, health recovery, and rehabilitation needs afterCOVID-19. The investigators will recruit patients and their informal caregivers forinterviews to assess their function and rehabilitation needs.

This study is to establish an accurate, robust and easily scalable COVID-19 viral nucleicacid analysis platform from, but not limited to, saliva to help enable and supportcontact tracing in the canton of Baselland/ Switzerland. To achieve this, cruderibonucleotide acid (RNA) extraction from saliva is validated in combination withnext-generation sequencing (NGS) diagnostics and loop mediated amplification (LAMP)assays as well as point of care test (POCT) for rapid detection of viral antigens onpatients' samples.

It is expected that large numbers of healthcare workers will experience a broad range ofpsychological reactions and symptoms including anxiety, depression, moral distress, andtrauma symptoms that will cause both significant suffering as well as occupational andsocial impairment. The purpose of this study is to find interventions which are helpfulin treating psychological distress in healthcare workers caring for COVID-19 patients.There are two phases of the study. All participants will take part in Phase I, whichconsists of 4 sessions over a two-week period of either a narrative writing interventionor a medical music intervention. Participants will be randomly assigned to the narrativewriting intervention or medical music intervention.After Phase I, participants will be re-assessed. Healthcare workers who meet criteria forPTSD will be given the option to participate in Phase II of the study, in which they willbe offered a choice between one of two evidence-based treatments for PTSD: InterpersonalTherapy (IPT) or Exposure Therapy (ET). Both treatments are comprised of ten 75-minutesessions scheduled twice weekly. Participants will be allowed to choose a preferredtreatment in Phase II. After Phase II participants will complete a final assessmentconcluding the study. All interventions will be offered using distance technology.

Although recognized as an autoimmune disease the etiology of type 1 diabetes remainsunknown. Virus infections has been suggested as a possible agent triggering theautoimmune reaction finally resulting in beta-cell destruction and fate of insulinsecretion. SARS Cov-2 virus enters the infected cells by binding to the ACE-2 receptor,which is abundant in many tissues including the pancreas. Accordingly, SARS Covid-19infection may trigger the development of type 1 diabetes either by an activation of theimmune system or directly via beta-cell infection and destruction.Our aim is to study the impact of the Covid-19 epidemic on the development of type 1diabetes. This will be done in two ways: a clinical study and an epidemiological followup. During the next two years, adult patients with newly diagnosed type 1 diabetes willbe asked to participate. Type 1 diabetes will be diagnosed by usual means and a mixedmeal tolerance test will be performed at time of diagnosis and after one year to evaluatebeta-cell function. People with type 1 diabetes and serologically documented previousSARS Covid-19 will be compared with people with no previous infection regarding beta-cellfunction and fate of insulin secretion. In addition, we will estimate the number of newdiagnosed type 1 diabetes patients compared to previous years.

The Coronavirus has caused containment of more than a third of the world's population.Containment can drastically change lifestyle habits, including eating habits such as thenumber of meals, meal times or their composition. However, there is currently no data onthe influence of confinement on eating habits.

Bone and soft tissue sarcomas represent about 7-12% of all pediatric cancer and are aheterogeneous group of tumors arising in connective tissues embryologically derived fromthe mesenchyme. For some of these tumors relapse and mortality rates are stillsignificantly high. Therefore, further studies are needed to better understandpathogenetic processes underlying sarcomas to offer new and more effective treatments.Next generation sequencing (NGS) has opened new frontiers for cancer research allowing toidentify somatic or constitutional mutations known or yet unknown with the aim to betterunderstand carcinogenesis. The establishment of the genomic profile of the tumor couldalso help clinicians to personalize patients treatment based on their genetic andmolecular alterations.

Coronavirus has caused containment of more than half of the world's population and amajor and rapid reorganization of clinical and support services. The spread ofcoronavirus (COVID-19) has posed significant challenges for occupational health services.However, there is currently no data on the influence of this epidemic on the practice andfeelings of dental surgeons and associates